Waterloo Capital L.P. Takes Position in Cencora, Inc. (NYSE:COR)

Waterloo Capital L.P. purchased a new position in Cencora, Inc. (NYSE:COR - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 2,854 shares of the company's stock, valued at approximately $641,000.

A number of other institutional investors have also recently made changes to their positions in the company. United Bank grew its holdings in shares of Cencora by 4.2% in the third quarter. United Bank now owns 5,601 shares of the company's stock valued at $1,261,000 after purchasing an additional 225 shares in the last quarter. Arete Wealth Advisors LLC increased its holdings in shares of Cencora by 4.9% in the 3rd quarter. Arete Wealth Advisors LLC now owns 2,412 shares of the company's stock worth $541,000 after buying an additional 113 shares during the last quarter. Quantinno Capital Management LP grew its position in Cencora by 78.6% in the third quarter. Quantinno Capital Management LP now owns 24,838 shares of the company's stock worth $5,591,000 after acquiring an additional 10,933 shares in the last quarter. EP Wealth Advisors LLC increased its stake in Cencora by 32.5% during the third quarter. EP Wealth Advisors LLC now owns 5,279 shares of the company's stock worth $1,188,000 after acquiring an additional 1,296 shares during the last quarter. Finally, iA Global Asset Management Inc. raised its position in Cencora by 400.5% during the third quarter. iA Global Asset Management Inc. now owns 7,087 shares of the company's stock valued at $1,595,000 after purchasing an additional 5,671 shares during the period. Hedge funds and other institutional investors own 97.52% of the company's stock.

Cencora Stock Up 1.9 %

Shares of COR stock traded up $5.31 during mid-day trading on Friday, hitting $284.46. 1,509,188 shares of the stock traded hands, compared to its average volume of 1,506,610. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The stock has a market cap of $55.16 billion, a P/E ratio of 40.46, a P/E/G ratio of 1.31 and a beta of 0.55. The stock's fifty day moving average is $260.27 and its two-hundred day moving average is $245.01. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $296.65.

Cencora (NYSE:COR - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Equities analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.77%. The ex-dividend date was Friday, February 14th. Cencora's dividend payout ratio is presently 31.29%.

Insider Transactions at Cencora

In other Cencora news, EVP Elizabeth S. Campbell sold 4,127 shares of Cencora stock in a transaction on Monday, March 24th. The shares were sold at an average price of $268.28, for a total value of $1,107,191.56. Following the completion of the transaction, the executive vice president now owns 14,665 shares of the company's stock, valued at approximately $3,934,326.20. The trade was a 21.96 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Lazarus Krikorian sold 2,000 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the sale, the chief accounting officer now directly owns 20,154 shares of the company's stock, valued at $5,241,249.24. This represents a 9.03 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,675 shares of company stock worth $8,034,778 over the last three months. 10.80% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on COR shares. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Wells Fargo & Company upped their price target on shares of Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a report on Friday, March 14th. Bank of America boosted their target price on Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research report on Friday. JPMorgan Chase & Co. increased their price target on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Finally, Evercore ISI upped their price objective on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $284.20.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.